EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer
Public ClinicalTrials.gov record NCT04892472. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a multicenter, randomized, open-label study of Tumor Treating Fields (TTFields) at 150 kHz to the thorax using the NovoTTF-200T System with IV pembrolizumab in subjects previously untreated for advanced or metastatic, PD-L1 positive non-small cell lung cancer (NSCLC). The primary objective is to evaluate the progression-free survival (PFS) by RECIST 1.1 in subjects with TPS ≥1 percent, 1L metastatic/current advanced NSCLC treated with TTFields concomitant with pembrolizumab compared to those treated with pembrolizumab alone. The device is an experimental, portable, battery operated device for chronic administration of alternating electric fields (termed TTFields) to the region of the malignant tumor, by means of surface, insulated electrode arrays.
Study identification
- NCT ID
- NCT04892472
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 15 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 22 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 12, 2021 (Actual)
- Primary completion
- Jan 10, 2025 (Actual)
- Completion
- Jan 10, 2025 (Actual)
- Last update posted
- Apr 23, 2025
2021 – 2025
United States locations
- U.S. sites
- 24
- U.S. states
- 17
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Central Alabama Research | Birmingham | Alabama | 35209 | — |
| Palo Verde Cancer Specialists | Glendale | Arizona | 85304 | — |
| Mayo Clinic | Phoenix | Arizona | 85054 | — |
| Long Beach Memorial Medical Center | Long Beach | California | 90806 | — |
| UCHealth Memorial Hospital | Colorado Springs | Colorado | 80909 | — |
| Cancer Care of North Florida | Lake City | Florida | 32024 | — |
| Miami Cancer Insititute - Baptist Health South Florida | Miami | Florida | 33716 | — |
| University of Illinois Hospital and Health Sciences System | Chicago | Illinois | 60612 | — |
| Parkview Research Center | Fort Wayne | Indiana | 46845 | — |
| Franciscan St. Francis Health Indianapolis | Indianapolis | Indiana | 46237 | — |
| Saint Elizabeth Healthcare | Edgewood | Kentucky | 41017 | — |
| Baptist Health Oncology Research | Lexington | Kentucky | 40503 | — |
| Michigan Center of Medical Research | Farmington Hills | Michigan | 48334 | — |
| Cancer and Leukemia Center | Sterling Heights | Michigan | 48314 | — |
| Cancer Partners of Nebraska | Lincoln | Nebraska | 68510 | — |
| OptumCare Cancer Care | Las Vegas | Nevada | 89102 | — |
| Arnot Ogen Medical Center - Falck Cancer Center | Elmira | New York | 14905 | — |
| Oncology Specialists of Charlotte | Charlotte | North Carolina | 28210 | — |
| Aultman Hospital | Canton | Ohio | 44710 | — |
| Gabrail Cancer Research Center | Canton | Ohio | 44718 | — |
| Lankenau Medical Center | Wynnewood | Pennsylvania | 19096 | — |
| Tennessee Cancer Specialists | Knoxville | Tennessee | 37909 | — |
| Texas Oncology - Sammons Cancer Center | Dallas | Texas | 75246 | — |
| : The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04892472, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 23, 2025 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04892472 live on ClinicalTrials.gov.